Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 2,795 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination Group Clear all

Conditions: Tonsillectomy
Interventions: Standard Care, ATC Dosing, Structured Pain Management Program, As needed dosing; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 6 Years to 15 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2012
U.S. locations: 1
States / cities: Madera, California

Conditions: Pain, Back Pain, Lower Back Pain, Quality of Life
Interventions: Dry Needling, Dry needling with high-rate PENS, Dry needling with low-rate PENS; Other
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Pain Management
Interventions: Morphine Sulfate, Oxycodone, Acetaminophen; Drug
Lead sponsor: Antonios Likourezos; Other
Eligibility: 18 Years to 64 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Type 2 Diabetes Mellitus, Hypertension
Interventions: Placebo, Sitagliptin, Aprepitant, Mixed Meal Test (MMT); Drug · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Smoking Cessation
Interventions: Contingency management, Nicotine replacement therapy, Varenicline, Additional behavioral support; Behavioral · Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer, Locally Advanced Breast Cancer
Interventions: Palazestrant, Ribociclib, Alpelisib, Everolimus, Atirmociclib; Drug
Lead sponsor: Olema Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 14
States / cities: Gilbert, Arizona • San Francisco, California • Aurora, Colorado + 11 more

Conditions: Malignant Neoplasm, Oral Pain, Stomatitis
Interventions: Best Practice, Methylene Blue; Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Traumatic Brain Injury With Brief Loss of Consciousness, Traumatic Brain Injury With No Loss of Consciousness
Interventions: Cognitive Rehab, Brainworks, Informational Handout/Provider Visits; Behavioral
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: IDH Mutation, IDH1 Mutation, IDH2 Gene Mutation, Blood Cancer, Myeloproliferative Neoplasm
Interventions: Ivosidenib, Enasidenib, Fedratinib; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes Mellitus, Type 2 Diabetes Mellitus, Adult-Onset Diabetes Mellitus, Non-Insulin-Dependent Diabetes Mellitus, Noninsulin Dependent Diabetes Mellitus, Type II
Interventions: High Frequency Financial Incentive, Moderate Frequency Financial Incentive, Low Frequency Financial Incentive; Behavioral
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 21 Years to 100 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Dizziness, Vertigo
Interventions: Vestibular Rehabilitation, Usual Care; Behavioral · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Schizophrenia
Interventions: Aripiprazole Lauroxil, Computerized cognitive and functional skills training; Drug · Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy Volunteer
Interventions: AVP-786, AVP-923; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Leishmaniasis
Interventions: GLA-SE, LEISH-F3, MPL-SE, SE; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Subacute Low Back Pain
Interventions: Progressive Exercise Plan, NeuromuscularElectricalStimulation(NMES), Primary Care Management (PCM); Behavioral · Device
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years to 45 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Fort Campbell North, Kentucky

Conditions: HIV Infections
Interventions: HIV LFn-p24; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Metastatic Castrate-Resistant Prostate Cancer
Interventions: Alobresib, Enzalutamide; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 4
States / cities: San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: HIV
Interventions: VRC07-523LS 400mg, PGT121.414.LS 400mg, PGDM1400LS 400mg, VRC07-523LS 3200mg, PGT121.414.LS 1600mg, PGDM1400LS 1600mg; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 13
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 8 more

Conditions: Leukemia
Interventions: filgrastim, asparaginase, cyclophosphamide, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, liposomal cytarabine, mercaptopurine, mesna, methotrexate, therapeutic hydrocortisone, thiotepa, vincristine sulfate, low-LET electron therapy, low-LET photon therapy; Biological · Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 20 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1996
U.S. locations: 62
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 48 more

Conditions: Healthy
Interventions: Motivational Interviewing, Education, Wearable Fitness Trackers, Wearable Fitness Tracker+; Behavioral
Lead sponsor: Colorado State University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Eczema, Atopic Dermatitis
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 2 Years to 100 Years
Enrollment: 530 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Smoking Cessation
Interventions: Bupropion, Nicotine patch, Varenicline; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 223 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hyperlipidemia
Interventions: Bococizumab 150mg, Bococizumab 75mg, Bococizumab 150mg placebo, Bococizumab 75mg placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 30
States / cities: Chandler, Arizona • Lincoln, California • Los Angeles, California + 25 more

Conditions: Neuroblastoma, High-risk Neuroblastoma, Metastatic Neuroblastoma
Interventions: OPT-821 (QS-21), oral β-glucan; Biological · Dietary Supplement
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Search by objective public record fields.

Home Care Management of Pediatric Pain

Pain Intervention With Needling: Pilot Of Integrated Neuromodulation Techniques

Analgesic Efficacy of (MSIR)/Acetaminophen vs. Oxycodone/Acetaminophen (Percocet)

Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure

A Smoking Cessation Intervention for Yale Dining Employees

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

MOM's PAIN (Methylene Blue for Oral Mucositis' PAIN)

The Study of Cognitive Rehabilitation Effectiveness for Mild Traumatic Brain Injury

A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms

Financial Incentives Telephone Education and Skills Trial in African Americans With Diabetes (FITEST)

Emergency Department Vestibular Rehabilitation Therapy for Dizziness and Vertigo

C-Cog in Early Course Schizophrenia Study

A Phase 1 Study Comparing AVP-786 With AVP-923

LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine

Subacute Low Back Pain in Active Duty

A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer

A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV

Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia

A Study to Test the Effectiveness of Different Interventions to Improve Physical Activity in Adults.

Studies of Skin Microbes in Healthy People and in People With Skin Conditions

Extended Treatment for Smoking Cessation

Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma